[
  {
    "ts": null,
    "headline": "Top 50 High-Quality Dividend Growth Stocks For December 2025",
    "summary": "See here for an analysis of 50 high-quality dividend growth stocks to identify timely, attractive investment opportunities.",
    "url": "https://finnhub.io/api/news?id=60576fb19e04759e332f80d617375cb7bf9abec445f08aafadc198ce3e09591f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765227824,
      "headline": "Top 50 High-Quality Dividend Growth Stocks For December 2025",
      "id": 137735866,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242367752/image_2242367752.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "See here for an analysis of 50 high-quality dividend growth stocks to identify timely, attractive investment opportunities.",
      "url": "https://finnhub.io/api/news?id=60576fb19e04759e332f80d617375cb7bf9abec445f08aafadc198ce3e09591f"
    }
  },
  {
    "ts": null,
    "headline": "Lilly declares first-quarter 2026 dividend",
    "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock.",
    "url": "https://finnhub.io/api/news?id=94c4307f8e87a105f4981b1bd499943bda7bd5a2a7bd126927f445825c736a8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765220700,
      "headline": "Lilly declares first-quarter 2026 dividend",
      "id": 137737709,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock.",
      "url": "https://finnhub.io/api/news?id=94c4307f8e87a105f4981b1bd499943bda7bd5a2a7bd126927f445825c736a8f"
    }
  },
  {
    "ts": null,
    "headline": "Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?",
    "summary": "Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.",
    "url": "https://finnhub.io/api/news?id=8ccde1e9188043d29f9e3b16a5a60ba25325e9ddddba86ad5887d50b1d28f2e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765219980,
      "headline": "Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?",
      "id": 137737710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.",
      "url": "https://finnhub.io/api/news?id=8ccde1e9188043d29f9e3b16a5a60ba25325e9ddddba86ad5887d50b1d28f2e3"
    }
  },
  {
    "ts": null,
    "headline": "Obesity Biotechs’ Gains Hit Shares of Eli Lilly, Novo Nordisk",
    "summary": "Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.",
    "url": "https://finnhub.io/api/news?id=dddab987adeb5f24b1a46be9cf211cabb1fee97359cf249d5d5290fed3e25c81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765215960,
      "headline": "Obesity Biotechs’ Gains Hit Shares of Eli Lilly, Novo Nordisk",
      "id": 137737711,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.",
      "url": "https://finnhub.io/api/news?id=dddab987adeb5f24b1a46be9cf211cabb1fee97359cf249d5d5290fed3e25c81"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy rating on the stock. The firm updated its models for LLY based on prescription trends and […]",
    "url": "https://finnhub.io/api/news?id=09cdd7b7f4e20b8a64ca0b8920e7762c8d3b311fa791c07d9711fcf6383fd2f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765215405,
      "headline": "Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”",
      "id": 137737712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy rating on the stock. The firm updated its models for LLY based on prescription trends and […]",
      "url": "https://finnhub.io/api/news?id=09cdd7b7f4e20b8a64ca0b8920e7762c8d3b311fa791c07d9711fcf6383fd2f7"
    }
  },
  {
    "ts": null,
    "headline": "Neuroblastoma Market - A Global and Regional Analysis: Focus on Treatment and Regional Analysis - Analysis and Forecast, 2025-2035",
    "summary": "Neuroblastoma, a rare cancer mainly affecting children, is witnessing advancements in treatments, notably through immunotherapy, which has improved survival rates. Key innovations like gene and CAR-T cell therapies are accelerated by substantial government and private investments, transforming market dynamics. However, high treatment costs pose a challenge, particularly in low-resource settings. Leaders like Novartis and Eli Lilly drive innovation, focusing on sustainable products. The market's",
    "url": "https://finnhub.io/api/news?id=ebdc8fd5dab3867ccdd9efefafb38528db2a282a5d6f87c00bee7300fe39c687",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765211640,
      "headline": "Neuroblastoma Market - A Global and Regional Analysis: Focus on Treatment and Regional Analysis - Analysis and Forecast, 2025-2035",
      "id": 137732191,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Neuroblastoma, a rare cancer mainly affecting children, is witnessing advancements in treatments, notably through immunotherapy, which has improved survival rates. Key innovations like gene and CAR-T cell therapies are accelerated by substantial government and private investments, transforming market dynamics. However, high treatment costs pose a challenge, particularly in low-resource settings. Leaders like Novartis and Eli Lilly drive innovation, focusing on sustainable products. The market's",
      "url": "https://finnhub.io/api/news?id=ebdc8fd5dab3867ccdd9efefafb38528db2a282a5d6f87c00bee7300fe39c687"
    }
  },
  {
    "ts": null,
    "headline": "Structure Therapeutics Soars; CEO Says It Could Have 'Best-In-Class' Weight-Loss Drug",
    "summary": "Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients.",
    "url": "https://finnhub.io/api/news?id=2f126baa017c5a241833249d4e52353b481b6ae97d277bcbafc9343fc3bf9cfc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765209306,
      "headline": "Structure Therapeutics Soars; CEO Says It Could Have 'Best-In-Class' Weight-Loss Drug",
      "id": 137732192,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients.",
      "url": "https://finnhub.io/api/news?id=2f126baa017c5a241833249d4e52353b481b6ae97d277bcbafc9343fc3bf9cfc"
    }
  },
  {
    "ts": null,
    "headline": "Top-Ranked ETFs to Power Your Portfolio Higher",
    "summary": "With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.",
    "url": "https://finnhub.io/api/news?id=09c653a2074e50b91ca5b1a50357c2a1f772e3bb6bf997344c8c5d344dbcbec6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765209180,
      "headline": "Top-Ranked ETFs to Power Your Portfolio Higher",
      "id": 137737705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.",
      "url": "https://finnhub.io/api/news?id=09c653a2074e50b91ca5b1a50357c2a1f772e3bb6bf997344c8c5d344dbcbec6"
    }
  },
  {
    "ts": null,
    "headline": "Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill",
    "summary": "Shares of Structure Therapeutics surged Monday after the biotechnology company said an experimental pill helped people lose substantial weight in a mid-stage clinical trial.  The trial results raised hopes for high sales in the booming obesity-drug market.  Analysts said the efficacy could make Structure’s pill competitive with Eli Lilly’s orforglipron, which Lilly hopes to introduce next year.",
    "url": "https://finnhub.io/api/news?id=ca858efcf0522f94ea4933ff29e1bee97eecd9257c85ca7c3b03582967afdecf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765208196,
      "headline": "Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill",
      "id": 137732193,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Structure Therapeutics surged Monday after the biotechnology company said an experimental pill helped people lose substantial weight in a mid-stage clinical trial.  The trial results raised hopes for high sales in the booming obesity-drug market.  Analysts said the efficacy could make Structure’s pill competitive with Eli Lilly’s orforglipron, which Lilly hopes to introduce next year.",
      "url": "https://finnhub.io/api/news?id=ca858efcf0522f94ea4933ff29e1bee97eecd9257c85ca7c3b03582967afdecf"
    }
  },
  {
    "ts": null,
    "headline": "Carolyn Bertozzi returns to Lilly board of directors",
    "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees.",
    "url": "https://finnhub.io/api/news?id=2d1293ad96aa9b58da965f0377e9536e15e984e72fa016ce9fc0ebc4c87df7c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765206000,
      "headline": "Carolyn Bertozzi returns to Lilly board of directors",
      "id": 137732194,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees.",
      "url": "https://finnhub.io/api/news?id=2d1293ad96aa9b58da965f0377e9536e15e984e72fa016ce9fc0ebc4c87df7c8"
    }
  },
  {
    "ts": null,
    "headline": "2026 Market Outlook: S&P 500 To 7600, Healthcare, Renewable Energy, Industrials Will Lead",
    "summary": "Discover why the S&P 500 could hit $7,600 by 2026, driven by AI, sector rotation, and strong consumer trends. Click for my look into the market's future.",
    "url": "https://finnhub.io/api/news?id=9cc1b002a6efaf1fddb5bd4fe481b718786c0396d00abeff24f5abc6760c3a0e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765205708,
      "headline": "2026 Market Outlook: S&P 500 To 7600, Healthcare, Renewable Energy, Industrials Will Lead",
      "id": 137734426,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1334805030/image_1334805030.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why the S&P 500 could hit $7,600 by 2026, driven by AI, sector rotation, and strong consumer trends. Click for my look into the market's future.",
      "url": "https://finnhub.io/api/news?id=9cc1b002a6efaf1fddb5bd4fe481b718786c0396d00abeff24f5abc6760c3a0e"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=856b23975e3a3576f6d7ff6beaf6b341631e4e200930d31781579b7f47884a2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765205104,
      "headline": "Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term",
      "id": 137732195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=856b23975e3a3576f6d7ff6beaf6b341631e4e200930d31781579b7f47884a2c"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?",
    "summary": "Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.",
    "url": "https://finnhub.io/api/news?id=4024810435f2dd56a947e9d807bd963a4acab3dc9792a6d05bf7ecf7635567dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765204020,
      "headline": "Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?",
      "id": 137732196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.",
      "url": "https://finnhub.io/api/news?id=4024810435f2dd56a947e9d807bd963a4acab3dc9792a6d05bf7ecf7635567dd"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
    "summary": "Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott’s medical device segment ... Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
    "url": "https://finnhub.io/api/news?id=92ace4c19bb14eb02948a808e2e8a12eeed025d2de91b01049574248f6471c2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765203681,
      "headline": "Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
      "id": 137732197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott’s medical device segment ... Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
      "url": "https://finnhub.io/api/news?id=92ace4c19bb14eb02948a808e2e8a12eeed025d2de91b01049574248f6471c2e"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: IBM Eyes Another AI Deal",
    "summary": "IBM will reportedly pay $11B for the data streaming company. Lilly, Pfizer, J&J in Chinaâs private insurance catalog. White House rolling out $12B in aid for farmers.",
    "url": "https://finnhub.io/api/news?id=3a3c499cd69efc9da8e1fd02397acddcaf504b138226db1ea77b156f9511ca81",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765178152,
      "headline": "Wall Street Breakfast Podcast: IBM Eyes Another AI Deal",
      "id": 137730932,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2181778905/image_2181778905.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "IBM will reportedly pay $11B for the data streaming company. Lilly, Pfizer, J&J in Chinaâs private insurance catalog. White House rolling out $12B in aid for farmers.",
      "url": "https://finnhub.io/api/news?id=3a3c499cd69efc9da8e1fd02397acddcaf504b138226db1ea77b156f9511ca81"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Prefers Buying Eli Lilly When People Are “Getting Antsy”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed, along with the tech battleground. A caller asked Cramer about an optimal entry point into the stock, and he replied: “I think that people now are getting antsy and thinking that it’s really breaking down. That’s probably when I want to start […]",
    "url": "https://finnhub.io/api/news?id=107ca0e96a79329efc3fc7e261dafd01fc5cbf61ad7db18a664b5a6f32dccfb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765171927,
      "headline": "Jim Cramer Prefers Buying Eli Lilly When People Are “Getting Antsy”",
      "id": 137732198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed, along with the tech battleground. A caller asked Cramer about an optimal entry point into the stock, and he replied: “I think that people now are getting antsy and thinking that it’s really breaking down. That’s probably when I want to start […]",
      "url": "https://finnhub.io/api/news?id=107ca0e96a79329efc3fc7e261dafd01fc5cbf61ad7db18a664b5a6f32dccfb3"
    }
  },
  {
    "ts": null,
    "headline": "Unilever spinoff Magnum Ice Cream debuts on Amsterdam stock market",
    "summary": "Unilever's ice cream spinoff is now the world's largest standalone ice cream business after debuting on the Amsterdam stock market.",
    "url": "https://finnhub.io/api/news?id=9817180c31303cbcd18399123d2f16abb2631c1cfc548322de5ce54bff047725",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765164336,
      "headline": "Unilever spinoff Magnum Ice Cream debuts on Amsterdam stock market",
      "id": 137733424,
      "image": "https://image.cnbcfm.com/api/v1/image/108179546-1753944293624-gettyimages-2099558495-dsc_7940_b5jd6fba.jpeg?v=1765179381&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Unilever's ice cream spinoff is now the world's largest standalone ice cream business after debuting on the Amsterdam stock market.",
      "url": "https://finnhub.io/api/news?id=9817180c31303cbcd18399123d2f16abb2631c1cfc548322de5ce54bff047725"
    }
  }
]